- Home
- ORGO vs HPI Comparison
ORGO vs HPI Comparison
Compare ORGO & HPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- HPI
- Stock Information
- Founded
- ORGO 1985
- HPI 2002
- Country
- ORGO United States
- HPI United States
- Employees
- ORGO N/A
- HPI N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- HPI Trusts Except Educational Religious and Charitable
- Sector
- ORGO Health Care
- HPI Finance
- Exchange
- ORGO Nasdaq
- HPI Nasdaq
- Market Cap
- ORGO 533.9M
- HPI 431.9M
- IPO Year
- ORGO N/A
- HPI N/A
- Fundamental
- Price
- ORGO $5.34
- HPI $16.18
- Analyst Decision
- ORGO Buy
- HPI
- Analyst Count
- ORGO 2
- HPI 0
- Target Price
- ORGO $5.50
- HPI N/A
- AVG Volume (30 Days)
- ORGO 1.7M
- HPI 64.7K
- Earning Date
- ORGO 05-08-2025
- HPI 01-01-0001
- Dividend Yield
- ORGO N/A
- HPI 8.97%
- EPS Growth
- ORGO N/A
- HPI N/A
- EPS
- ORGO N/A
- HPI N/A
- Revenue
- ORGO $482,043,000.00
- HPI N/A
- Revenue This Year
- ORGO $3.31
- HPI N/A
- Revenue Next Year
- ORGO $12.50
- HPI N/A
- P/E Ratio
- ORGO N/A
- HPI N/A
- Revenue Growth
- ORGO 11.29
- HPI N/A
- 52 Week Low
- ORGO $2.17
- HPI $12.85
- 52 Week High
- ORGO $6.71
- HPI $16.83
- Technical
- Relative Strength Index (RSI)
- ORGO 67.16
- HPI 58.76
- Support Level
- ORGO $5.14
- HPI $15.71
- Resistance Level
- ORGO $5.42
- HPI $15.99
- Average True Range (ATR)
- ORGO 0.28
- HPI 0.19
- MACD
- ORGO 0.09
- HPI 0.11
- Stochastic Oscillator
- ORGO 85.09
- HPI 94.04
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About HPI John Hancock Preferred Income Fund of Beneficial Interest
John Hancock Preferred Income Fund is a closed-end, diversified management investment company. Its primary investment objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. It seeks to achieve its investment objectives by investing in securities that may be undervalued relative to similar securities in the marketplace. The fund's principal investment strategies include investing a majority of its assets in preferred stocks and other preferred securities. Its portfolio composition consists of U.S preferred securities, common stocks, foreign preferred securities, corporate bonds, and short-term investments.